Risk Classification in High Dimensional Survival Models by Amin, Daven
University of Rhode Island 
DigitalCommons@URI 
Open Access Master's Theses 
2016 
Risk Classification in High Dimensional Survival Models 
Daven Amin 
University of Rhode Island, amind@my.uri.edu 
Follow this and additional works at: https://digitalcommons.uri.edu/theses 
Recommended Citation 
Amin, Daven, "Risk Classification in High Dimensional Survival Models" (2016). Open Access Master's 
Theses. Paper 958. 
https://digitalcommons.uri.edu/theses/958 
This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion 
in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, 
please contact digitalcommons@etal.uri.edu. 
RISK CLASSIFICATION IN HIGH DIMENSIONAL SURVIVAL MODELS
BY
DAVEN AMIN
A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE
REQUIREMENTS FOR THE DEGREE OF
MASTER OF SCIENCE
IN
STATISTICS
UNIVERSITY OF RHODE ISLAND
2016
MASTER OF SCIENCE THESIS
OF
DAVEN AMIN
APPROVED:
Thesis Committee:
Major Professor Steffen Ventz
Gavino Puggioni
Corey Lang
Nasser H. Zawia
DEAN OF THE GRADUATE SCHOOL
UNIVERSITY OF RHODE ISLAND
2016
ABSTRACT
Sparse regression models are an actively burgeoning area of statistical learning
research. A subset of these models seek to separate out significant and non-trivial
main effects from noise effects within the regression framework (yielding so-called
“sparse” coefficient estimates, where many estimated effects are zero) by imposing
penalty terms on a likelihood-based estimator. As this area of the field is relatively re-
cent, many published techniques have not yet been investigated under a wide range
of applications. Our goal is to fit several penalty-based estimators for the Cox semi-
parametric survival model in the context of genomic covariates on breast cancer sur-
vival data where there are potentially many more covariates than observations. We
use the elastic net family of estimators, special cases of which are the LASSO and
ridge regression. Simultaneously, we aim to investigate whether the finer resolution
of next-generation genetic sequencing techniques adds improved predictive power
to the breast cancer patient survival models. Models are compared using estimates
of concordance, namely the c-statistic and a variant which we refer to as Uno’s C. We
find that ridge regression models best fit our dataset. Concordance estimates suggest
finer resolution genetic covariates improve model predictions, though further work
with more observations is required.
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CHAPTER 1
Introduction and Background
Information is being collected at an ever-increasing rate, yet more information
does not guarantee its holder more knowledge. The areas of statistical learning and
machine learning have erupted with new techniques to automate the process of
gleaning knowledge from massive stores of information. This thesis is an exploration
of a sliver of these methods, applied to a specific problem domain: cancer progress
prediction through genomic sequencing. We investigate whether finer-grained ge-
nomic information, available through newer sequencing methods, provides addi-
tional predictive power over the previous resolution of information.
1.1 Gene Expression
The central dogma of molecular biology describes the mechanisms by which
information encoded at a cellular level is expressed as proteins by an organ-
ism (Crick et al., 1970). In a simplified form, it suggests information, which partially
determines the physical traits of the organism, is encoded as linear sequences of de-
oxyribonucleic acid (DNA). This information is used to construct proteins, large three
dimensional structures which facilitate nearly all cellular functions within the organ-
ism. A gene is a sequence of DNA that maps to a particular protein, and the genome
comprises all genes. Genes are expressed as proteins through a series of steps. DNA is
transcribed into an intermediate ribonucleic acid (RNA) form, and the RNA sequence
is spliced to remove non-coding “intron” regions and join the remaining protein-
coding “exon” regions into new contiguous sequences (Gilbert, 1978). The order and
sequence of the exon regions determines the specific protein variant which will be
generated. Multiple splicing variants of a gene may exist. The splicing variants of
a gene, referred to as its “isoforms”, use different arrangements and subsets of ex-
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Figure 1. Genes, encoded as DNA, are expressed as proteins through a multi-stage
process beginning with transcription into RNA. Protein coding exon regions are then
spliced and translated into protein structures. Gene expression can be measured by
counting mRNA splicing variants. The expression can either be treated as the sum or
the set of all mRNA counts derived from a gene. Source: National Human Genome
Research Institute
ons. Spliced RNA sequences are translated directly into protein structures by cellular
mechanisms. Gene expression can be thought of as either the sum of all proteins de-
rived from a single gene’s DNA or specific levels of the protein variants derived from
a gene’s set of isoforms.
Many diseases, such as breast cancer, arise from corruption of the genetic code
within exon regions (the exome) (Bishop, 1987). Cancer is the manifestation of un-
controlled cell growth. Since cellular functions are dependent on protein, excessive
upregulation of protein production can increase cell reproduction. Similarly, cer-
tain regulatory functions are maintained through protein structures. In these cases,
downregulation of these proteins could also result in increased cell reproduction.
The cell constantly dismantles and regenerates many proteins in order to facilitate
these regulation mechanisms. Measuring the level of gene expression within a cell is
an indicator of protein activity. This thesis aims to compare isoform-level expression
information with overall gene expression in cancerous cells.
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1.2 Survival Models
A survival model, or time-to-event model, is a set of assumptions made about
the survivor function of a random event. The survivor function, denoted S(t ), is de-
fined as the probability of the random event occurring after some time t , denoted
Pr(T > t ) where T is the random variable time of event and both t and T are defined
in relation to a common starting time. The survivor function is the complement of
the cumulative distribution function of T (Kleinbaum and Klein, 1996). We assume
the event will eventually occur such that T is strictly positive and continuous. Some-
times T is referred to as the “failure time”. If we assume S(t ):
• equals 1 when t = 0 (the event cannot occur until some time has passed),
• is non-increasing for t > 0, and
• approaches 0 as t→∞ (the event must occur given infinite time).
then we can show S(t ) has a one-to-one relationship with a hazard function h(t )
which represents the instantaneous rate of the event occurring at time t given that it
has not yet occurred. The relationship between survivor function and hazard func-
tion is given by
h(t )=−[dS(t )/dt
S(t )
]
S(t )= e−
∫ t
0 h(u)du .
The hazard at time t is a rate, not a probability, and has less restrictions on its
form. Namely, a valid hazard function yields non-negative values for all values of
t and integrates to infinity over the positive real line. By modeling a valid hazard
function we’ve effectively modeled a valid survivor function using the relationships
shown above.
Modeling the hazard function allows us to answer questions in a similar fashion
to modeling the log-odds of the event occurring, such as the determination of risk
3
factors in a logistic regression. However, the hazard function explicitly accounts for
the passage of time. This can yield more information from “right-censored” obser-
vations when fitting a model. Right-censored observations are when the event must
have occurred after a time ti , but we do not know the actual time-of-event. Mod-
eling the log-odds ignores the censoring time ti and only considers the absence of
the event. Modeling the hazard rate, however, uses both censoring times and time
of events during the model fitting, as discussed below in the specific case of the Cox
proportional hazards model.
1.2.1 The Cox Proportional HazardsModel
One way to model the effect of covariates on the time of a random event uses
the approach of hazard regression. If the covariates X are unchanging with respect to
time, their effect on the hazard function can be modeled as h(t |X )= h(t )g (X ) where
g (X ) > 0. A popular model family for this conditional hazard is based on the Cox
semi-parametric proportional hazards model (Cox, 1972). The Cox model assumes
that the ratio of two rates with different covariates, i.e. conditional hazard ratio, for
the same event is constant and a function of the covariates. The covariates modify
the shared underlying hazard function h0(t ), denoted as the baseline hazard.
h(t |Xi )
h(t |X j )
= e(Xi−X j )β
h(t |Xi )= h0(t )×eXiβ
logh(t |Xi )= γ(t )+Xiβ
S(t |Xi )= S(t |X j )exp((Xi−X j )β)
The log hazard equation above shows how the Cox model may be seen as a gen-
eralized linear model (Nelder and Baker, 1972), where the intercept γ(t ) contains the
baseline hazard and a log link is used to estimate the hazard rate rather than an
expected value. Extensions to the Cox model allow for time-varying covariate ef-
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fects (Fisher and Lin, 1999) but lose the ability to predict individual survivor func-
tions. In this thesis, however, we do not consider any time-varying covariates.
The Cox model is semi-parametric as it assumes linear covariate effects (
∑
Xiβ)
on the hazard rate and it fits the effects β (also referred to as the coefficients of the
model) to observations using maximum likelihood of a partial likelihood function
which does not specify the baseline hazard. A fully parametric model with a tradi-
tional likelihood function would have to specify, and thus make assumptions about,
the baseline hazard. The partial likelihood function, LPL(β), for the Cox model is
given by
LPL(β)=
∏
r∈D
exp(X jrβ)∑
j∈Rr exp(X jβ)
where D is the set of event times, Rr is the set of observations at risk of the event
at time r , and jr is the observation with the event at time r (Tibshirani et al., 1997).
Maximum partial likelihood suggests the values ofβwhich produce the highest value
of the partial likelihood function given a dataset are the best estimates for the true
parameters of the model. In general, maximum partial likelihood estimation is solved
as an optimization problem. For mathematical and computational convenience, this
is often reformulated as maximizing the log partial likelihood function logLPL(β), and
the maximum partial likelihood estimator (MPLE) of β, βˆ, is given by
βˆ= argmax
β
{logLPL(β)}.
Fitting a Cox model allows a researcher to make probabilistic statements about
relative risk (i.e a patient who smokes has twice the risk of experiencing a heart attack
as one who does not smoke, all else being equal.) If the covariates are continuous, eβ j
can be considered a the change in relative risk due to a one unit change of covariate
X j .
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1.3 RegularizedModels
In problems where there are more unknown parameters to be fitted than obser-
vations, the Cox model is over-parameterized; that is, more than one combination of
parameter estimates maximize the partial likelihood function. Some other informa-
tion would be needed to distinguish the “best” set of parameter estimates. Modifying
this over-parameterized model such that the MPLE yields a single unique estimate
is termed “regularizing” the model. If a regularized likelihood function is convex, the
MPLE of the regularized model may be estimated using efficient convex optimization
techniques. This is important to fit models on large datasets in a reasonable amount
of time (i.e. hours or days!)
Moreover, if it is known apriori that not all, or possibly just a few, covari-
ates affect the time of the outcome event then the model should also account
for this. The assumption of relatively few true covariate effects is termed “spar-
sity” (James et al., 2013; Hastie et al., 2015). This thesis considers several cases of one
family of regularization methods which exploit the sparsity assumption. In these
methods β is estimated using a “penalized” estimator which can be written as
βˆ∗ = argmax
β
{logLPL(β)−λPT (β)}.
λ is a free parameter which dictates the bias towards 0 exerted by a penalty
term PT (β), where PT (β) ≥ 0. If λ = 0 and the model is not over-parameterized,
βˆ∗ yields the maximum likelihood estimate given by βˆ. As λ approaches ∞, the es-
timator βˆ∗ becomes smaller and smaller, with all covariate effects becoming 0. A
penalized estimator will give estimates which are biased towards 0. In the context
of prediction this property may be advantageous even if the underlying model is not
over-parameterized. If the data contain many “noisy” measurements or covariates
which do not truly influence the outcome, reducing the magnitudes of the estimated
covariate effects may reduce model overfitting.
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1.3.1 Ridge Regression, LASSO, and Elastic Net
The ridge (Hoerl and Kennard, 1970) estimator is a penalized estimator which
uses a penalty term of the squared Euclidean distance, or L22 norm, of the coefficients.
The L22 norm of β is defined as ∥∥β∥∥22 =∑
j
β j
2.
This norm shrinks coefficients towards zero as λ increases, but the estima-
tor does not produce sparse estimates. Rather, all coefficients are reduced in
magnitude. Hoerl et al. originally defined the ridge estimator in the context of
multiple linear regression, where they proved the ridge estimator always has a
value of λ for which it produces β estimates with lower mean squared error than
the regular Ordinary Least Squares estimator. Further work by Cessie and oth-
ers (Le Cessie and Van Houwelingen, 1992) showed this is asymptotically true for a
ridge estimator in the case of logistic regression, and that a ridge estimator can be
applied to the Cox model (Verweij and Van Houwelingen, 1994). Additionally, the
penalty function used to find the ridge estimator is convex and so the ridge estimator
is unique and may be found quickly even for large datasets.
A related penalized estimator is the LASSO (Tibshirani, 1996), or lasso, estima-
tor. LASSO is short for Least Absolute Shrinkage and Selection Operator. The lasso
estimator uses a penalty term of the Manhattan distance, or the L1 norm, of the coef-
ficients. The L1 norm of β is defined as
∥∥β∥∥1 =∑
j
∣∣β j ∣∣ .
The L1 norm has several useful properties which have boosted the popularity of
the lasso. It is the “smallest” of the Lp family of norms (in terms of p) which is convex,
and so it yields an estimator with a convex penalty function (Hastie et al., 2015). The
“smallest” member of the Lp family of penalty terms is the L0 generalized norm which
is optimal for variable selection, as it corresponds to best subset selection where the
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Figure 2. The lasso tends to produce sparse coefficient estimates, while the ridge es-
timator shrinks all estimates towards zero. In the case of estimating two coefficients,
the free parameter λ in the lasso estimator dictates the size of a square region (left)
corresponding to the L1 norm penalty, while the ridge estimator’s L22 penalty creates
a circular constraint (right). The estimators return the values in the parameter space
closest to the maximum likelihood estimate (βˆ) which meet their constraints. In the
case of the lasso, this tends to be on a vertex of the square (or edge of the hypercube
in higher dimensions), yielding one or more coefficient estimates of zero. Source:
Statistical Learning with Sparsity
likelihoods of all combinations of inclusions for predictor variables are considered.
Best subset selection, however, requires computational resources which are infeasi-
ble for non-trivial problems. The L1 norm as a penalty term tends to remove predictor
variables from fitted models, allowing the lasso estimator to yield “sparse” estimates.
The use of the L1 penalty also has the propensity to shrink small-magnitude covari-
ate effects to 0 while leaving large-magnitude effects close to their unbiased MPLE
estimates. However, if the covariates are highly correlated the lasso estimator will
arbitrarily shrink one effect towards zero.
The elastic net (Zou and Hastie, 2005) estimator attempts to yield sparse esti-
mates similar to the lasso while imposing uniform shrinkage on the effects of covari-
ates by using a weighted combination of the L1 and L22 norms as the penalty term.
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It introduces a second free parameter, α ∈ (0,1), and uses the weighted combination
(α
∥∥β∥∥1+ 12 (1−α)∥∥β∥∥22) as the penalty term. It can be thought of as a generalization
of the ridge and lasso estimators.
Bayesian Interpretation
These estimators can also be considered in the context of the Bayesian frame-
work. The Bayesian view of modeling focuses on obtaining the posterior distribution
of a model’s coefficients Pr(β|D), given an observed dataset D = (Y ,C ,X ) (composed
of time-to-events Y , censoring indicators C , and covariates X ) and a prior (possibly
uninformative) distribution of the model coefficients Pr(β). This posterior distribu-
tion is proportional to model likelihood multiplied by the prior distribution.
Pr(β|D)∝ Pr(D|β)Pr(β)
Pr(β|D)∝ L(β)Pr(β)
The “maximum a-posteriori” or MAP estimate of β can be obtained as the mode
of Pr(β|D) and is equivalent to maximizing logPr(β|D), yielding the equation
MAPβ = argmax
β
{logL(β)+ logPr(β)}.
Using the partial likelihood for the Cox model, the ridge estimator is equivalent
to the MAP estimator where the effects βi have i.i.d Gaussian prior distributions such
that
βi
i.i.d∼ N (0, 1
2λ
)
(Hastie et al., 2015). The lasso estimator is equivalent to a MAP estimator using
i.i.d Laplacian prior distributions on each βi , centered at zero and with spread pa-
rameters determined by λ. The elastic net is equivalent to a MAP estimator using a
mixture of penalty terms as the i.i.d priors on each βi .
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Figure 3. Comparison of Laplace and Gaussian distributions with identical location
and scale parameters (0 and 1, respectively). The Laplace distribution places more
probability mass at its central value and in its tails than the Gaussian distribution.
This characteristic is indicative of the lasso estimator’s sparsity properties.
1.4 Model Assessment
Many techniques to order statistical models from “better” to “worse” quantify
the “fit” of each model. That is, they use criteria derived from each model’s likelihood
function. A well fitting model can then be interpreted in the context of its assump-
tions.
In contrast, we are interested in comparing the predictive power of our estimated
models. Several measures have appeared in the literature, such as the cross-validated
partial likelihood, Brier Score, and pseudo R2 (Van Wieringen et al., 2009). Cross-
validated partial likelihood is based on the model likelihood function, discussed pre-
viously and is presented in our results. Here we discuss another measure of predictive
power for a single model (concordance), one of its interpretations (area under a re-
ceiver operating characteristics curve), and a variant of a common estimator for it.
Due to the asymptotic normality of the estimator we can test for differences in pre-
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dictive power between models, which we also present in our results.
1.4.1 Concordance and Receiver Operating Characteristics Curves
Concordance is defined as
concordance= P (pred(X1)> pred(X2)|T1 < T2)
where (Ti ,Xi ), i = 1,2 are two independent failure times and covariate sets and
pred(Xi ) is a predictor of the hazard rate as a function of the covariates. The es-
timated linear predictor, βˆXi , is used as pred(Xi ) in the case of Cox and penal-
ized Cox models. In the absence of right-censoring the concordance is equivalent
to the area under a Receiver Operating Characteristics (ROC) curve for the given
model (Hanley and McNeil, 1982) and is related to the sensitivity and specificity of
the model.
The ROC curve for a predictive model with two outcomes is a graphical represen-
tation of the model’s ability to correctly predict observations experiencing the event
or “positive” observations, referred to as sensitivity, as the tolerance for incorrect pos-
itive predictions or “false positives” ranges from nil to unbounded.
In a binary outcome scenario, where outcomes are “true” or “false” and we have
a set of covariates for each “true” or “false” observation, a model which computes a
score based on the covariates can be considered to predict a “true” outcome if the
score is above a fixed threshold and “false” otherwise. The model’s performance can
be evaluated according to its sensitivity and specificity. The sensitivity is the propor-
tion of true positives (the outcome was “true” and the model predicted “true”) among
all “true” observations, and the specificity is the proportion of true negatives (the out-
come was “false” and the model predicted “false”) among all “false” observations. As
seen in Table 1, a confusion matrix showing the expected distribution of model pre-
dictions against actual outcomes can be constructed from the model’s sensitivity and
specificity along with a set of outcomes.
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Model: “true” Model: “false” Total
Actual: “true” sensitivity × P (1-sensitivity) × P P
Actual: “false” (1-specificity) ×N specificity ×N N
Table 1. A confusion matrix giving the expected distribution of a model’s prediction
outcomes in terms of its sensitivity and specificity, given some P “true” outcomes and
N “false” outcomes.
The ROC curve plots specificity against sensitivity as the threshold for class pre-
diction is varied. The horizontal axis denotes (1-specificity) and the vertical axis de-
notes (sensitivity).
A model which has no predictive power will appear as a straight line between
0,0 (denoting the threshold at which all observations are classified as “false”), and
1,1 (denoting the threshold at which all observations are classified as “true”) since
for any given threshold the proportion of true positives (sensitivity) is equal to the
proportion of false positives (1-specificity). The area under this curve (AUC) is .5. The
AUC of a model which always correctly classifies “true” observations is 1, since the
proportion of true positives (sensitivity) equals 1 regardless of the proportion of false
positives (1-specificity). If a model has an AUC less than .5 (a misclassifier) it can be
converted to one with an AUC greater than .5 by swapping the predicted classification
of observations.
There are several methods to assess whether two models fitted on the same ob-
servations have statistically different AUCs including those based on the asymptotic
normality of concordance (DeLong et al., 1988).
1.4.2 C-Statistics
Survival models model time-to-event, not binary outcome, and must use
adapted ROC methods. Instead of computing the full ROC curve to determine
the AUC, a prevalent estimator of concordance for a survival model is the c-
statistic (Lee and Mark, 1996). The c-statistic is computed by first taking all pairs of
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observations where at least observation is not right-censored and assigning each pair
a class label. The label is
• “concordant” if the observation with a smaller failure time experienced the
event and had a higher predicted hazard than the other,
• “discordant” if the observation with a smaller failure time had a lower predicted
hazard, or
• “tied” if the predicted hazards are equal and only one observation of the pair
experienced the event.
Pairs where the observation with the smaller failure time did not experience the
event are discarded, as are pairs where both observations experienced the event at
the same time.
The c-statistic is defined as
c− statistic= concord+ .5(tied)
concord+discord+ tied
where concord is the number of concordant pairs, discord is the number of dis-
cordant pairs, and tied is the number of tied pairs.
If all observations experienced the event, the c-statistic is an unbiased estimator
of concordance. In the presence of right-censoring the distribution of the c-statistic
is dependent on the censoring distribution and may no longer directly estimate the
concordance (Koziol and Jia, 2009).
We note that detecting whether a survival model has increased predictive power
over another may not be possible by the comparing the concordances if both models
have reasonable predictive power (Pencina et al., 2008).
However, the use of concordance is still prevalent in the literature without a
widely accepted alternative, though work is ongoing to introduce new measures
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of predictive power such as variants of the Integrated Discrimination Improve-
ment (Uno et al., 2013). We use the variant of the c-statistic from (Uno et al., 2011)
to remove the effect of the censoring distribution on the estimate of concordance
and test for differences in predictive discrimination between models.
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CHAPTER 2
Methodology
Our dataset is part of data generated by The Cancer Genome Atlas Research
Network (TCGA), a collaborative project between the National Cancer Institute
(NCI) and the National Human Genome Research Institute (NHGRI). TCGA provides
anonymized genomic and clinical data for major types and subtypes of cancer and
makes the data freely available for research.
Specifically, we are focused on patient mortality of female breast cancer patients.
We obtained two slices of TCGA’s BRCA dataset from the Firehose portal of the Broad
Institute (Broad Institute TCGA Genome Data Analysis Center, 2016), one containing
clinical covariates and survival outcome of 1097 breast cancer patients and the other
containing RSEM (Li and Dewey, 2011) estimated counts of gene isoforms for 1212
tissue samples.
2.1 Cleaning
The Firehose portal provides aggregated outputs from a pipeline sequence of
tools. However, the raw output was not in a format immediately ready for analysis.
Specifically, the data was organized in row-column format such that each row corre-
sponded to a covariate (cancer stage, patient age, gene expression count) and each
column corresponded to a patient. We used a set of R (R Development Core Team, )
and Python (VanRossum and Drake, 2010) helper routines to transpose the raw data
into a row-column format where each row represents a patient (an observation) and
each column represents a variable of interest. Separate cleaning and transformation
steps were required by each dataset (gene expression counts and survival time & clin-
ical covariates) before merging the two for analysis in R as detailed below.
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2.1.1 RSEMData
In order to give researchers the ability to explore many aspects of breast cancer
gene expression, the BRCA data contains gene expression estimates of tissue samples
from breast tumors and normal non-cancerous regions. Though the underlying gene
expression counts are integers, the RSEM count estimates take on real values. We re-
moved the 112 normal tissue samples from the data, leaving 1100 sets of breast tumor
gene expression estimates, with each set containing 73,599 isoform count estimates.
Equivalence of Gene and IsoformCounts
Although it was not used in our analysis, TCGA provides other datasets, includ-
ing gene-level expression estimates. We aggregated the isoform expression dataset
at the gene-level and compared it to the provided gene-level estimates to verify our
aggregation procedure was correct. All (patient,gene-level) counts were within .01
units, which we attribute to rounding precision. We used this as justification for
working directly with the isoform expression dataset and later aggregating it at the
gene-level. 6229 isoforms out of the 73,599 total did not correspond to a known gene.
We verified this was an anomaly of the underlying dataset and not an artifact of our
procedures or an error. Although outside of the scope of this thesis, these isoforms do
not map to a known gene in the HG19 reference genome used by the RSEM procedure
to create expression count estimates. These isoforms were included in the normaliza-
tion procedures detailed below if they exhibited non-trivial variance among patients,
but are excluded from the analysis as we cannot compare them to a gene-level aggre-
gate.
Removal of low-variance Isoform Counts
Many of the isoform expression estimates were zero for all patients. Since we
are only interested in isoforms which have an effect on survival time, we removed
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Figure 4. Histogram of log sample variance for estimated isoform counts in the origi-
nal TCGA dataset. Isoforms with log sample variance less than or equal to zero were
removed from the data.
all isoforms with low sample variance of expression counts among patients. Figure 4
shows the histogram of log sample variance for each isoform across all patients. Iso-
forms with log sample variance less than or equal to 0 were excluded from all subse-
quent cleanup and analysis, and are ignored for the rest of this thesis. 67,027 isoforms
had sample variances of at least 1 and were not excluded, and 63,214 isoforms had a
known gene correspondence. Although the 67,027 isoforms were used in the normal-
ization procedures, our final RSEM data contained information from 63,213 isoforms
corresponding to 19,330 genes.
Between andWithin Sample Normalization
The isoform expression estimates are dependent on the amount of tissue sam-
pled (with more biomass we would expect to see higher estimated counts) and need
to be rescaled. A common scaled unit which we adopt is “counts per million” or CPM,
which is just a scaled sample proportion of each estimated count per gene or isoform
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Gene Patient 1 Count Patient 2 Count Patient 1 CPM Patient 2 CPM
1 2 6 .2 .06
2 2 6 .2 .06
3 2 6 .2 .06
4 2 6 .2 .06
5 2 76 .2 .76
Table 2. An example of within-sample normalization using counts per million (CPM)
yielding misleading results: it is more likely that genes 1–4 are expressed identically
in patients 1 and 2, while only gene 5 is differentially expressed. CPM normalization
only considers the number of counts within each patient and yields a result suggest-
ing all five genes are differentially expressed. Source: Harold Pimentel
i in patient j . In this section we will use the term “gene” to refer to both gene-level
aggregates and isoforms when describing normalization techniques.
CPM, defined as
CPMi , j =
counti , j∑
i
count j
×106
only normalizes counts relative to a patient, or within-sample. An example
from (Pimentel, 2014) illustrates the issue with this well; if we have counts from 5
genes for two patients where genes 1–4 are known to be expressed identically but
gene 5 is expressed several orders of magnitude more in patient 2, we end up with the
misleading CPMs shown in Table 2.
We need to normalize counts between patients as well in order to compare
them. This requires the use of a between-sample normalization method. One
method by (Bullard et al., 2010) uses an upper quantile based method to correct for
between-sample differences. Normalized count data is available from Firehose us-
ing this method. We use the normalization method and implementation described
by (Li et al., 2011) in which the “sequencing depth” of each patient is estimated using
a log-linear model. They define sequencing depth as a measure of the relative counts
between patients. In the example from Table 2 the sequencing depth of patient 2
would be 3 relative to patient 1, since genes 1–4 had raw counts three times higher
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but are expected to show identical expression in both patients.
The normalization method is iterative, and uses half of the measured genes to
estimate sequencing depth under the assumption that gene expression counts come
from a Poisson distribution where the mean µi , j count for patient i and gene j is
equal to the expression level of j scaled by the sequencing depth of i . A simplified
description and example of the method in action is described below.
• In the initial step, the sequencing depth is estimated as the proportion of each
patient’s total gene counts. For the example in Table 2, the proportion vector
would be approximately (0.09,0.91), by taking the marginal counts of (10,100)
and dividing by the sum.
• Next, each total gene count is scaled by the current estimation of the sequenc-
ing depth. For Table 2, this would yield
0.73 7.27
0.73 7.27
0.73 7.27
0.73 7.27
7.10 70.90
These are the “expected” gene counts given the sequencing depth and the
marginal gene counts.
• A goodness-of-fit (GOF) metric is calculated for each gene by summing the
squared difference of the observed count and the expected count from the pre-
vious step divided by the expected count per gene patient pair.
GOF= ∑
gene
(observedcount−expectedcount)2
expectedcount
For the example, we have a GOF vector of approximately (2.23+ 0.22,2.23+
0.22,2.23+0.22,2.23+0.22,3.66+0.37) or (2.45,2.45,2.45,2.45,4.02).
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• The genes with GOF values within the first and third quartiles of the GOF vector
are used to estimate the sequencing depth as in the initial step, and the proce-
dure repeats. In the example, genes 1–4 would be used to estimate sequencing
depth in the next iteration, and gene 5 would be ignored. When the estimates
of sequencing depth remain nearly constant between iterations, the procedure
can be terminated.
Our estimates of sequencing depth are summarized in Figure 5 and Table 3. The
normalization procedure centers the final estimates around 1. The implementation
also pre-filters genes with overall small counts before starting the procedure – this
yielded 3012 isoforms out of 67,027 being filtered. We scaled each patient’s isoform
counts by the estimated sequencing depth to perform between-sample normaliza-
tion. We then added 1 to each normalized count before converting each patient’s
normalized counts to CPM, guaranteeing all CPM values are greater than zero and
allowing us to perform logarithmic transformations during the analysis.
Min. :0.2779 Max. :2.2771
Mean :1.0396 Median :1.0290
1st Qu.:0.8360 3rd Qu.:1.2304
Table 3. Descriptive statistics of estimated sequencing depth distribution. n = 1100.
2.1.2 Survival Times and Censoring
We used the “clinical pick” merged dataset, which contains high-level clini-
cal covariates and survival outcomes for 1097 patients. We created the dependent
variable time (time of event or censoring time) by using the “days_to_death” field
when available or “days_to_last_followup” if missing. We also created a censor-
ing indicator variable censoring with a value of 1 if days_to_death was used or 0 if
days_to_last_followup was used.
The dataset contained observations from 12 males with breast cancer, of which
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Figure 5. Relative histogram and smoothed density estimate of estimated sequencing
depth distribution. Histogram counts have been scaled such that the total shaded
area is equal to 1.
11 were censored observations. We removed these observations, yielding 1085 obser-
vations of female breast cancer patients, where 150 patients suffered mortality during
their observation period and 14 were missing both a time of event and a censoring
time. The median survival time was 3941 days. The Kaplan-Meier survival curve,
along with 95% confidence intervals, is shown in Figure 6.
2.1.3 Merged Data and Clinical Covariates
We merged the isoform CPM transformed data and filtered “clinical pick” data
using the common patient identifiers. This yielded a merged dataset containing 1074
observations. These observations contained all of the high-level clinical covariates
from the “clinical pick” dataset.
We considered including several clinical covariates in our analysis as controlling
variables. Originally we considered including “years_to_birth”, “radiation_therapy”,
“number_of_lymph_nodes”, “pathologic_stage”, and “race”. Age and number of
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Figure 6. Kaplan-Meier estimate of the survivor function ˆS(t ) of the original dataset,
after removing male observations, denoted as the solid line. The 95% confidence
interval is shown as the dotted band.
23
lymph nodes are integer valued, while the other covariates are categorical. Several
issues with these covariates were identified and addressed. In all cases, the trans-
formation or omission of a covariate does not drastically affect our analysis, as our
goal does not involve interpretation of covariate effects, only a comparison of models
which share clinical covariates.
“Pathologic_stage”, which is an assessment of the severity of the cancer at the
time of initial diagnosis, contains several levels where all patients survived. Fitting
a Cox model on survival using this covariate is not possible due to numerical issues
and a lack of convergence in the fitting procedure. We avoided this issue by creating a
new categorical variable, stage, where the stages were collapsed down into five levels
(one for each major stage of cancer, and a fifth for the cases where cancer stage was
not determined or missing).
pathologic_stage Censored Deceased
stage i 77 13
stage ia 82 3
stage ib 6 0
stage ii 5 0
stage iia 319 34
stage iib 220 29
stage iii 0 2
stage iiia 129 26
stage iiib 18 8
stage iiic 53 9
stage iv 5 14
stage x 7 7
NA 6 2
stage Censored Deceased
1 165 16
2 544 63
3 200 45
4 5 14
unknown 13 9
Table 4. Counts of “pathologic_stage” and collapsed stage variables, tabulated against
survival outcome. “NA” and “stage x” were collapsed into the “unknown” level.
“Race” yielded a similar problem – the only “american indian or alaska native”
was censored, and a number of patients did not have a recorded race. We elected to
omit “race” as a categorical covariate.
We ran a standard Cox model on the remaining clinical covariates;
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“race” Censored Deceased
american indian or alaska native 1 0
asian 58 3
black or african american 151 29
white 630 108
NA 87 7
Table 5. Counts of the “race” variable tabulated against survival outcome.
“years_to_birth”, “radiation_therapy”, “number_of_lymph_nodes”, and stage. The
results suggest that “number_of_lymph_nodes” does not have a statistically signifi-
cant effect on survival outcome when adjusting for the other covariates. This is likely
due to the high correspondence between it and the stage variable. We omitted this
covariate from further analysis as well. We used a likelihood ratio test to verify our
decision to exclude “number_of_lymph_nodes”. The fitted Cox model and likelihood
ratio test are shown in Table 6.
coef exp(coef) se(coef) z p
years_to_birth 0.03 1.03 0.01 3.41 0.00
radiation_therapyyes -0.66 0.52 0.23 -2.84 0.00
number_of_lymph_nodes 0.03 1.03 0.02 1.44 0.15
stage2 0.75 2.11 0.41 1.80 0.07
stage3 1.67 5.30 0.45 3.67 0.00
stage4 2.44 11.53 0.56 4.38 0.00
stageunknown 0.89 2.43 0.81 1.10 0.27
loglik Chisq Df P(>|Chi|)
with lymph -463.92
without lymph -464.89 1.93 1 0.1647
Table 6. Cox model estimates, along with Wald statistics and associated p-values for
each coefficient where stage1 is the reference class, and Likelihood Ratio Test (LRT)
of the model compared to a model with the lymph node covariate excluded. “num-
ber_of_lymph_nodes” is the only coefficient with a statistically insignificant p-value.
The LRT suggests there is not a statistically significant difference between the two
models.
Our final dataset consisted of survival outcome, “years_to_birth”, “radia-
tion_therapy”, stage, and RSEM covariates for each patient. Patients with missing
information were omitted. This left 967 observations, with 109 events and 858 cen-
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Figure 7. Kaplan-Meier estimate of the survivor function ˆS(t ) for the merged data
denoted as the solid line. The 95% confidence interval is shown as the dotted band.
The removal of additional observations (mostly censored) has raised the curve and
increased the median observed survival time.
sored cases. The median survival time increased to 6456 days. The Kaplan-Meier
survival curve is shown in Figure 7.
2.2 Filtering
Although the methods we use during the analysis fit over-parameterized mod-
els, the resulting covariate effect estimates are still limited by the number of observa-
tions. In particular, the lasso estimator will return at most 967 coefficient estimates.
This is just over 1% of the isoform covariates! While the ridge estimator will return
coefficient estimates for all covariates, it is unlikely that these will represent the true
effects due to the lack of power. In order to increase the chances of fitting models with
meaningful predictive power, we reduced the number of isoform covariates by con-
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ducting per-variable selection procedure while correcting for multiple testing using
a local false discovery rate (fdr) threshold.
2.2.1 Per-Variable Models
We fit a standard Cox model for each individual isoform which has a known cor-
respondence to a gene (63,213 isoforms), where each model contained only the single
isoform covariate. As is common in genomic analysis of CPMs, the base-2 logarith-
mic transformation was taken on each covariate.
For each model, we collected the probability of estimating a covariate effect at
least as large as the model’s estimated effect under a null hypothesis where the true
covariate effect is 0 (the p-value for the covariate). This was done using a Likelihood
Ratio Test (LRT): the scaled difference between log likelihoods of models with and
without the effect comes from a χ2 distribution with one degree of freedom if the
models are equivalent, as the sample size goes to infinity (Wilks, 1938).
These are plotted in Figure 8 against the theoretical distribution of p-values un-
der the null hypothesis, i.e. a Uniform 0,1 distribution. The deviation between the
observed p-value distribution and the theoretical distribution suggests there are iso-
form covariates which do have a nonzero effect on patient survival time despite the
large number of tests (and subsequent inflation of the overall Type 1 error rate). Some
of the counts from Figure 8 are broken out in Table 7.
# models 63213
# non-NA 63213
# <= .05 5417
# <= .001 215
Table 7. Counts of per-isoform Cox models and models with extremely low p-values.
Isoform filtering is based on a later correction to meet a false discovery rate threshold
due to multiple testing.
We aggregated the isoform counts into gene-level counts, yielding 19,330 gene
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Figure 8. Relative histogram of binned p-values of isoform covariates in univariate
per-isoform Cox models, compared to the theoretical distribution under the null as-
sumption of no effect on survival time. The difference in distributions suggests the
null assumption does not hold.
level covariates. We then repeated the same univariate modeling procedure, yielding
Figure 9. Strangely enough, several of the isoform and gene aggregated covariates
were duplicated among patients. The full list of genes which had at least one dupli-
cated isoform among all patients is given in Table 8.
ACSBG2|81616 MCCC1|56922 RBMY1J|378951
AK2|204 NR1I3|9970 RBMY2FP|159162
HNRNPC|3183 POLDIP3|84271 SEPT7|989
KDM5D|8284 RBMY1A1|5940 TMEM161A|54929
VDAC3|7419
Table 8. Gene names where at least one constituent isoform had expression estimates
duplicated across all patients.
2.2.2 Multiple Testing Correction
As alluded to in the previous section, conducting 63,213 or 19,330 tests (in the
case of isoform or gene-level testing, respectively) constitutes a multiple testing is-
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Figure 9. Relative histogram of binned p-values of gene-level covariates in univariate
per-aggregate Cox models, compared to the theoretical distribution under the null
assumption of no effect on survival time. The resulting plot is similar to Figure 8.
sue. Under the assumption of isoform independence and the null hypothesis, we’d
expect to see 3160 isoforms with a p-value less than 0.05. That is, even if all isoform
expression levels have no effect on patient survival time (assuming all isoform expres-
sion levels are independent of one another) we’d likely find a large number spurious
correlations between expression and survival time relative to the number of patients
in our dataset.
One approach to identifying and separating the “interesting” isoforms or
genes from those with spurious correlations is to control the local false discovery
rate (Efron and Tibshirani, 2002). We assume there are two underlying classes of co-
variates (“interesting” and “unimportant”) and that each isoform or gene covariate
belongs to one of the two classes. “Unimportant” covariates are assumed to have no
“true” effect on patient survival time, while “interesting” covariates have a nonzero
effect. We assume each covariate has a η0 probability of being “unimportant” and a
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1−η0 probability of being “interesting”. If the “unimportant” and “interesting” co-
variates are identically distributed within their classes, the p-values, denoted y , from
the per-covariate models follow a mixture density
f (y)= η0 f0(y)+ (1−η0) f1(y)
where f0 is the density function of the “unimportant” p-values and f1 is the den-
sity function of the “interesting” p-values. Since f0 is the density function of the null
hypothesis, we can define the probability of a covariate being “unimportant” given
its p-value equals y as
fdr(y)= η0 f0(y)
f (y)
which is the definition of the local false discovery rate, or fdr. Here, f0 is a Uni-
form 0,1 density. We use the R package “fdrtool” (Strimmer, 2008) to estimate both
ηˆ0 and ˆf (y) and construct the set of fdr probabilities for each isoform and gene-level
covariate.
ηˆ0 was estimated at 0.8408 for the isoform mixture and 0.7772 for the gene-level
mixture. This makes sense; there is likely a higher proportion of “noise” covariates at
the isoform level than when they are collapsed down into aggregates representing an
overall gene level.
We plotted an unscaled version of the empirical cumulative distribution func-
tion (CDF) for the estimated fdr values in Figures 10 and 11.
We used a cutoff threshold of 0.20; that is, accepting covariates with an estimated
probability of being “unimportant” given their p-value – a false discovery – less than
0.20. This yields 81 isoforms from the per-isoform model p-values and 298 genes
from the per-gene model p-values.
The 81 isoforms with estimated fdr values less than or equal to 0.20 correspond
to 76 unique genes. To make a fair comparison between isoform-level and gene-level
models in the analysis, we consider the set of 76 unique gene covariates against their
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Figure 10. Empirical CDF of per-isoform estimated fdr values. The dashed line rep-
resents the 967 observations and meets the CDF at a cutoff value of 0.367. This is
a rough indication of when the number of covariate effects to be estimated will be
greater than the number of observations.
Figure 11. Empirical CDF of per-gene estimated fdr values. The dashed line repre-
senting the 967 observations meets the CDF at a cutoff value of 0.330.
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constituent 332 isoform variants (including the 81 “interesting” isoforms). The 298
“interesting” genes correspond to 914 isoform variants.
2.3 Analysis
We fit a battery of penalized models to the merged and filtered dataset. Two
overall sets of models were fit to the data. Both sets of models were fit with the high-
level clinical covariates. The first set of models included the genetic covariates de-
termined by the isoforms with significant univariate association with overall survival
after controlling for a false discovery rate of 0.20. The second set included the genetic
covariates based on gene-level aggregates with significant associations with overall
survival after controlling for the same false discovery rate. In all cases, the log base2
transformation of the CPM was used.
2.3.1 Cross-Validated Loss
We performed a grid search to assess the impact ofα and λ on the fit of the data.
α is the model parameter which determines the proportion of the L1 and L2 norms
in the penalty term of the elastic net, where α= 0 corresponds to the LASSO and α=
1 corresponds to ridge regression. λ is the model parameter which determines the
magnitude of the penalty term, where λ= 0 corresponds to an unpenalized model.
Quality of fit was determined using the cross-validated loss pro-
cedure of (Simon et al., 2011) as implemented in the package “glm-
net” (Friedman et al., 2013). The goodness-of-fit for a model is given by splitting
the dataset into a series of “folds”, and estimating the model parameters for each
partition of the dataset which excludes a “fold”. The difference between the partial-
likelihood of the estimated parameters on the full dataset and the partial-likelihood
of the estimated parameters on the partition is taken, and the sum of the differences
is the cross-validated loss. The values of λ which minimize the cross-validated loss
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are considered to “best” fit the data.
However, if the number of folds is less than the number of observations, the par-
titioning of the data is not necessarily unique and the cross validation procedure
should be repeated to assess the impact of this variability. We opted to eliminate
this variability by finding the cross-validated loss using leave-one-out cross valida-
tion (LOOC) where partition contained all but one observations. This guarantees that
each partition is unique and that the estimated model parameters found will not vary.
2.3.2 Concordance
We computed the c-statistics using the procedure implemented in the package
“survival” (Therneau, 2016) for the subset of the models in our cross validated grid
search which had the “best” values of λ for a given α parameter.
We also compared isoform and gene-aggregate models using the variant of the
c-statistic implemented in the package “survC1” (Uno, 2013). We provided the risk
scores for the cross validated models specified above as univariate predictors and
computed the concordance. We then tested the difference in concordance for sta-
tistical significance between the model corresponding to the gene-aggregate covari-
ates and the model corresponding to their constituent isoform covariates, given a
fixed value of α and each model’s “best” value of λ according to the cross-validation
procedure. This procedure was run for both sets of covariates, those determined by
isoform-level filtering as well as those determined by gene-level filtering.
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CHAPTER 3
Results and Conclusions
3.1 Cross-validatedModel Fitting
We present the results of the cross-validated loss procedure and discuss the fits
and number of nonzero coefficient estimates for isoform and gene-aggregate models.
Cross-validated loss per observation, ˆCV i , as described previously (2.3.1), is de-
fined mathematically as a function of λ and α:
ˆCV i (λ,α)= `( ˆβ−i (λ,α))−`−i ( ˆβ−i (λ,α))
where ` is the partial-likelihood function of the complete dataset, `−i is the
partial-likelihood function of the dataset excluding the i th observation, and ˆβ−i are
the coefficient estimates for the dataset excluding the i th observation. We used leave-
one-out cross-validated (LOOC) loss, the mean over ˆCV i for all i observations, to
compare isoform and gene-aggregate models. We sometimes refer to LOOC loss as
the overall cross-validated loss.
The values of overall cross-validated loss are show in Tables 9 and 10 for each
value of α in our grid search and the corresponding value of λ which minimized the
loss.
3.1.1 Isoform-basedModels
Table 9 refers to models fit with the 332 isoform covariates or 76 gene-aggregate
covariates, along with the selected clinical variables. These versions of the covariates
correspond to the set of isoforms which were found to have high levels of agreement
with survival outcome during the univariate filtering procedure. The form of the co-
variates (whether broken out by isoform or lumped together as a gene-aggregate) is
denoted by the “type” column.
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type alph lambda cvm cvsd nzero gzero percnzero
iso 0.00 0.14 10.00 0.08 338 76 1.00
gene 0.00 0.11 10.58 0.07 82 76 1.00
iso 0.10 0.06 10.10 0.08 171 69 0.91
gene 0.10 0.05 10.57 0.07 56 51 0.67
iso 0.20 0.04 10.15 0.08 131 62 0.82
gene 0.20 0.04 10.58 0.07 49 44 0.58
iso 0.30 0.03 10.18 0.09 113 58 0.76
gene 0.30 0.03 10.59 0.07 44 39 0.51
iso 0.40 0.02 10.21 0.09 104 57 0.75
gene 0.40 0.02 10.59 0.07 40 35 0.46
iso 0.50 0.02 10.23 0.09 94 54 0.71
gene 0.50 0.02 10.59 0.07 38 33 0.43
iso 0.60 0.02 10.25 0.09 92 53 0.70
gene 0.60 0.02 10.60 0.07 37 32 0.42
iso 0.70 0.02 10.27 0.08 78 48 0.63
gene 0.70 0.02 10.60 0.07 35 30 0.39
iso 0.80 0.02 10.29 0.08 69 44 0.58
gene 0.80 0.01 10.60 0.07 35 30 0.39
iso 0.90 0.02 10.29 0.08 69 44 0.58
gene 0.90 0.01 10.59 0.07 36 31 0.41
iso 1.00 0.01 10.30 0.08 69 44 0.58
gene 1.00 0.01 10.59 0.07 33 28 0.37
Table 9. Summary of cross-validated loss in models fit to the covariates determined
by univariate filtering at the isoform level. For each given level of α, the model with
the lowest value of mean cross-validated loss (“cvm”) over all possible values of λ is
shown. Models run on the 332 constituent isoforms are labeled as “iso” type, and
those run on the 76 gene-level aggregates are labeled as “gene” type. The standard
deviation (“cvsd”) and number of non-zero model coefficient estimates (“nzero”) are
displayed. For comparison purposes, we’ve added the number and proportion of
the 76 genes represented by at least one non-zero isoform or aggregate coefficient
estimate in the “gzero” and “percnzero” columns.
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The cross validated loss (“cvm” column) for all of the 11 penalized models is
lower for models fit on the “iso” type of covariates and the lowest loss occurs when
using the ridge estimator (α = 0). The ridge estimator does not perform variable se-
lection and thus produces non-zero coefficient estimates for all 332 isoform covari-
ates or all 76 gene-aggregate covariates (as well as the 6 clinical variables) as shown
in the “nzero” column. As more weight is placed on the L1 norm in the penalty term,
the number of variables in the model drops to 69 and 33 respectively when using the
LASSO estimator (α = 1). We’ve added a column representing the number of the 76
genes which are represented by at least one non-zero coefficient estimate (“gzero”)
to facilitate comparison between the variable selections in both types of models. The
models fit on the “iso” type of covariates always represent variants of the same or
more unique genes than those fit on the “gene” type of covariates and even the LASSO
estimator produces a model with over half of the genes represented. The proportion
of genes with non-zero coefficient estimates is shown in the “percnzero” column.
The grid search over λ andα on these covariates is denoted in Figures 12 and 13.
The models which minimize the loss tend to have a number of null or zero coefficient
estimates (with the exception of the ridge estimator model), even for low values of α.
As α decreases, the value of λ for the model with the lowest loss increases.
3.1.2 Gene-basedModels
Table 10 refers to models fit with the 914 isoform covariates or 298 gene-
aggregate covariates selected by univariate filtering on the gene-aggregate covariates,
along with the selected clinical variables.
The relationship of cross validated loss (“cvm” column) for all of the 11 penalized
models is reversed from the previous section; for any given value ofα, the loss is lower
for models fit on the “gene” type of covariates. As before, the lowest loss occurs when
using the ridge estimator (α = 0). The number of covariates removed as α increases
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type alph lambda cvm cvsd nzero gzero percnzero
iso 0.00 0.33 10.45 0.08 920 298 1.00
gene 0.00 0.14 10.37 0.08 304 298 1.00
iso 0.10 0.09 10.55 0.08 261 170 0.57
gene 0.10 0.05 10.45 0.08 141 135 0.45
iso 0.20 0.05 10.59 0.08 190 133 0.45
gene 0.20 0.04 10.46 0.07 92 87 0.29
iso 0.30 0.05 10.62 0.07 125 98 0.33
gene 0.30 0.03 10.48 0.07 80 75 0.25
iso 0.40 0.03 10.62 0.07 115 90 0.30
gene 0.40 0.03 10.52 0.07 75 70 0.23
iso 0.50 0.03 10.64 0.08 112 88 0.30
gene 0.50 0.02 10.55 0.07 69 64 0.21
iso 0.60 0.02 10.66 0.08 119 92 0.31
gene 0.60 0.02 10.56 0.07 68 63 0.21
iso 0.70 0.02 10.67 0.08 115 88 0.30
gene 0.70 0.02 10.57 0.07 64 59 0.20
iso 0.80 0.02 10.68 0.07 79 64 0.21
gene 0.80 0.01 10.58 0.07 64 59 0.20
iso 0.90 0.02 10.67 0.07 77 63 0.21
gene 0.90 0.01 10.59 0.07 63 58 0.19
iso 1.00 0.02 10.67 0.07 73 61 0.20
gene 1.00 0.01 10.59 0.07 62 57 0.19
Table 10. Summary of cross-validated loss in models fit to the covariates determined
by univariate filtering at the gene-aggregate level. For each given level ofα, the model
with the lowest value of mean cross-validated loss (“cvm”) over all possible values of
λ is shown. Models run on the 914 constituent isoforms are labeled as “iso” type, and
those run on the 298 gene-level aggregates are labeled as “gene” type. The standard
deviation (“cvsd”) and number of non-zero model coefficient estimates (“nzero”) are
displayed. For comparison purposes, we’ve added the number and proportion of
the 298 genes represented by at least one non-zero isoform or aggregate coefficient
estimate in the “gzero” and “percnzero” columns.
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and more weight is placed on the L1 norm is also much greater than in the previous
section, though this is likely an artifact of the larger number of covariates overall.
The column representing the number of the 298 genes which are represented
by at least one non-zero coefficient estimate (“gzero”) shows that, as in the previous
section, models fit on the “iso” type of covariates always represent the same or more
unique genes than those fit on the “gene” type of covariates.
The grid search over λ andα on these covariates is denoted in Figures 14 and 15.
3.1.3 Comparison
The relationship between the models fit on the isoform-filtering covariates and
the gene-filtering covariates is shown in Figure 16. The reversed relationship between
“type” and “cvm” is visible. The cross-validated loss is lowest for models fit on isoform
covariates determined by isoform-level univariate filtering, but is highest for models
fit on isoform covariates determined by gene-level univariate filtering.
3.2 Concordance
We present high level results of concordance measures for the models presented
in the previous section. Concordance was computed on the observations of the mod-
els fit above. Rationale and shortcomings of this approach are treated in the discus-
sion.
3.2.1 C-Statistics
The c-statistic, as defined previously in 1.4.2, of the linear predictor, βˆXi , for all
the models in Tables 9 and 10, is given in Tables 11 and 12.
The relationship between the “iso” and “gene” models remains consistent be-
tween both sets of covariates. For both sets of covariates, “iso” type models have
a higher point estimate of concordance than “gene” type models. The most concor-
dant models are often those fit using the ridge estimator. Both sets of covariates show
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similar high concordance along the range ofα values when used in “iso” type models.
type alph lambda c-statistic
iso 0.00 0.14 0.95
gene 0.00 0.11 0.87
iso 0.10 0.06 0.94
gene 0.10 0.05 0.87
iso 0.20 0.04 0.94
gene 0.20 0.04 0.86
iso 0.30 0.03 0.94
gene 0.30 0.03 0.86
iso 0.40 0.02 0.94
gene 0.40 0.02 0.86
iso 0.50 0.02 0.93
gene 0.50 0.02 0.86
iso 0.60 0.02 0.94
gene 0.60 0.02 0.86
iso 0.70 0.02 0.93
gene 0.70 0.02 0.86
iso 0.80 0.02 0.92
gene 0.80 0.01 0.86
iso 0.90 0.02 0.92
gene 0.90 0.01 0.86
iso 1.00 0.01 0.92
gene 1.00 0.01 0.86
Table 11. C-statistics for each model from Table 9. These models were fit to the set of
covariates determined by univariate filtering at the isoform-level. “iso” models were
fit to the set of 332 constituent isoforms and “gene” models were fit to 76 gene-level
aggregates.
3.2.2 Uno’s C
We used Uno’s C estimator to re-estimate concordance and obtain an estimate of
the standard error. Uno’s C (along with standard errors) are shown graphically against
the c-statistics in Figure 17. Since the sampling distribution of Uno’s C is asymptoti-
cally normal, we constructed confidence intervals for the difference in concordance
between “iso” and “gene” type models and present the results in Tables 13 and 14.
The differences are also shown graphically in Figure 18.
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type alph lambda concordance
iso 0.00 0.33 0.96
gene 0.00 0.14 0.92
iso 0.10 0.09 0.95
gene 0.10 0.05 0.92
iso 0.20 0.05 0.95
gene 0.20 0.04 0.91
iso 0.30 0.05 0.93
gene 0.30 0.03 0.91
iso 0.40 0.03 0.93
gene 0.40 0.03 0.91
iso 0.50 0.03 0.93
gene 0.50 0.02 0.91
iso 0.60 0.02 0.94
gene 0.60 0.02 0.91
iso 0.70 0.02 0.94
gene 0.70 0.02 0.91
iso 0.80 0.02 0.92
gene 0.80 0.01 0.91
iso 0.90 0.02 0.92
gene 0.90 0.01 0.91
iso 1.00 0.02 0.92
gene 1.00 0.01 0.91
Table 12. C-statistics for each model from Table 10. These models were fit to the set of
covariates determined by univariate filtering at the isoform-level. “iso” models were
fit to the set of 914 constituent isoforms and “gene” models were fit to 298 gene-level
aggregates.
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alph concordance stderr lower95 upper95
0.00 -0.11 0.02 -0.15 -0.07
0.10 -0.11 0.02 -0.15 -0.07
0.20 -0.11 0.02 -0.15 -0.07
0.30 -0.11 0.02 -0.15 -0.07
0.40 -0.11 0.02 -0.15 -0.07
0.50 -0.11 0.02 -0.14 -0.07
0.60 -0.11 0.02 -0.15 -0.07
0.70 -0.10 0.02 -0.14 -0.06
0.80 -0.09 0.02 -0.13 -0.05
0.90 -0.09 0.02 -0.13 -0.05
1.00 -0.09 0.02 -0.13 -0.06
Table 13. Difference in Uno’s C between each “gene” and “iso” pair from Table 11.
The difference is given in the “concordance” column. A negative difference indicates
Uno’s C is higher for the “iso” level model. The standard error of the difference and
a 95% confidence interval based on the asymptotic distribution of the difference are
reported as well.
alph concordance stderr lower95 upper95
0.00 -0.06 0.01 -0.09 -0.03
0.10 -0.04 0.01 -0.07 -0.02
0.20 -0.05 0.01 -0.08 -0.03
0.30 -0.03 0.01 -0.05 -0.01
0.40 -0.03 0.01 -0.05 -0.01
0.50 -0.04 0.01 -0.06 -0.02
0.60 -0.05 0.01 -0.07 -0.02
0.70 -0.05 0.01 -0.07 -0.02
0.80 -0.02 0.01 -0.04 -0.00
0.90 -0.02 0.01 -0.04 -0.00
1.00 -0.02 0.01 -0.04 0.00
Table 14. Difference in Uno’s C between each “gene” and “iso” pair from Table 12.
The difference is given in the “concordance” column. A negative difference indicates
Uno’s C is higher for the “iso” level model. The standard error of the difference and
a 95% confidence interval based on the asymptotic distribution of the difference are
reported as well.
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3.3 Final Models
We have two types of models we wish to compare and two sets of covariates they
were fit on. We refer to these four categories by shorthand, where the first designation
gives the pre-selection covariate group and the second gives the granularity of the
model covariates. Iso-iso models are fit on the covariates pre-selected by isoform-
level filtering and genomic covariates are represented by isoform log2 CPM (“iso” type
models). Iso-gene models are fit on the set of gene-aggregated covariates (“gene” type
models) pre-selected by isoform-level filtering. Gene-iso and gene-gene models are
similar but fit on the set of covariates pre-selected by gene-level filtering.
We are particularly interested in iso-iso models and gene-gene models. Gene-
gene models represent the pre-selection and model fitting possible before next-
generation sequencing techniques, while iso-iso models represent the finer grained
pre-selection and fitting possible with RSEM.
We found that fixing α = 0 and searching over λ minimized the cross-validated
loss for both of these model categories. The resulting estimated models are equiv-
alent to those found using the ridge estimator. We focus our discussion of concor-
dance on these ridge models for the iso-iso and gene-gene categories. We refer to
these ridge models as the iso-iso and gene-gene models.
The c-statistic for the iso-iso model is higher than the gene-gene model. This
suggests that models created and fit on the finer grained covariates have increased
predictive power. We used the asymptotic normality of Uno’s C estimator to construct
a 95% confidence interval for the difference in concordance between the iso-iso and
gene-gene models. The difference, presented in Table 15, was statistically signifi-
cant. Again, this suggests that isoform counts provide increased predictive power
compared to gene-level counts.
We present Kaplan-Meier estimated survivor curves per model for patients strat-
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Model Est SE Lower95 Upper95
Gene-Gene 0.89 0.02 0.85 0.93
Iso-Iso 0.94 0.01 0.92 0.96
Difference -0.05 0.02 -0.09 -0.02
Table 15. Estimates of Uno’s C for the iso-iso and gene-gene models, along with 95%
confidence intervals. The 95% confidence interval for the difference in estimates,
based on the asymptotic normality of the estimator, suggests the difference in esti-
mates is statistically significant.
ified by median risk score in Figures 19 and 20. The curves are estimated using the
same observations used to fit the models. As is the case with the concordance esti-
mates, the curves likely overestimate model performance. However, we assume the
difference between the curves is still indicative of the true difference between mod-
els. Test statistics from log-rank tests on the stratifications are given in Table 16.
Model χ2d f =1
Iso-Iso 198
Gene-Gene 142
Table 16. Test statistics for log-rank tests for the final ridge models. Tests were on
the association between survival outcome and whether the patient’s risk score was
below the median risk but used the same set of observations the models were fit on.
However, there is a large difference in the χ2 values between the two models.
3.4 Discussion
We present a short summary of the work performed and discuss the final models.
Shortcomings in our methodology and further work are outlined.
3.4.1 Summary
Our intention is to investigate whether isoform-level expression information im-
proves cancer survival predictions as compared to overall gene expression.
Our investigation is focused on women with breast cancer from the TCGA’s BRCA
datasets. One dataset contained high level clinical covariates and survival time for
1097 patients. Another contained RSEM estimated isoform counts sequenced from
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Figure 19. Kaplan-Meier estimate of the survivor functions ˆS(t ) of patients stratified
by risk score in the iso-iso ridge model.
Figure 20. Kaplan-Meier estimate of the survivor functions ˆS(t ) of patients stratified
by risk score in the gene-gene ridge model.
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1212 tissue samples, of which 1100 belong to breast tumors. We found that pa-
tient age, cancer stage, and the presence of radiation therapy were clinical covariates
strongly associated with survival outcome.
The original RSEM data contained estimated counts for 73,559 isoforms per
sample. However, many of these estimated counts were always 0 or exhibited ex-
tremely low variance. We took the sample variance of each isoform and ignored iso-
forms with a sample variance less than or equal to 1.
We normalized the remaining RSEM data between cancerous tissue samples by
estimating and correcting for the “sequencing depth”. We then added one to all cor-
rected counts and converted them to CPM, or counts per million. Isoforms without
a known gene correspondence were ignored, leaving 63,213 isoform (or 19,330 gene-
level aggregate) counts for each sample.
Merging the two datasets yielded 967 observations of women breast cancer pa-
tients. 109 women died under observation. We performed variable pre-selection at
the isoform and the gene-aggregate levels yielding two sets of covariates (“isoform-
level filtering” and “gene-level filtering”). Pre-selection involved fitting a univariate
Cox model for each covariate and collecting the p-value associated with a likelihood
ratio test of the model. The set of p-values were corrected to control for the false
discovery rate, and we selected the covariates which had a corrected p-value below
0.20.
Our models are fit on either the log2 transform of CPM (“iso” type models) or
the log2 transform of CPM aggregates (“gene” type models), along with the clinical
covariates. We performed a grid search to minimize cross-validated loss over the free
parameters, α and λ, of the elastic net penalized Cox model. When α= 0 the penalty
term reduces to the ridge penalty, and when α= 1 the model fits the LASSO.
We found that the ridge models minimized the cross-validated loss for our model
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categories of interest, “iso” models fit to covariates determined by “isoform-level fil-
tering” and “gene” models fit to covariates determined “gene-level filtering”. We com-
puted estimates of concordance for the ridge models that minimized cross-validated
loss and tested the difference in concordance for significance. We also estimated
Kaplan-Meier survival curves for each model, stratifying observations by relationship
to the median risk score.
3.4.2 Investigation of Final Models
Our results suggest there is a difference in the predictive power between our final
models. The concordance estimate for the iso-iso model is higher than for the gene-
gene model. When we created a 95% confidence interval for the difference using the
asymptotic normality of Uno’s C, we found the interval did not contain 0 and that the
difference was statistically significant.
Ridge models do not perform variable selection and estimate non-zero effects
for all covariates. This suggests the difference in concordances is partially due to the
difference between the univariate filtering procedures. The filtering procedures se-
lected two sets of genes with non-trivial differences. 43 common genes were selected
by both procedures. This leaves 33 different genes out of the 76 selected by only the
isoform-level filtering, and 255 different genes out of the 298 selected by only the
gene-level filtering procedure.
It is of particular interest that the iso-iso model had a higher concordance esti-
mate than the gene-gene model. The isoform filtering showed a higher proportion
of “unimportant” isoforms. Additionally, isoform counts exhibit greater variability
than genes, since the latter are aggregate counts. The results suggest that despite this
increase in noise and variability, isoform level information may provide meaningful
advantages over gene-level information.
Furthermore, the concordance estimates suggest that both of these models
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have increased predictive performance compared to models fit on clinical covari-
ates alone. Repeating our methodology on just the clinical covariates yielded a ridge
model which minimized the cross-validated loss across the grid search of α and λ.
The estimated c-statistic of this model was 0.79 and the value of Uno’s C was 0.717,
with a 95% confidence interval of (0.649,0.785). Both final models with genomic co-
variates had statistically significant higher estimates of concordance, validating our
assumption that genomic information has a non-trivial association with breast can-
cer survival.
3.4.3 Shortcomings
We used the same observations to fit each model and then to compute the con-
cordance measurements. An ideal methodology would have computed the concor-
dance on a separate set of observations. However, we would have to create this set by
partitioning our data and this would have caused some issues due to the low number
of events within the dataset. Our dataset had 109 observations with a known failure
time. Reducing this number would introduce non-trivial additional variation in the
estimated models dependent on the choice of partitioning. Similarly, concordance is
estimated using the relationship between observations with at least one known fail-
ure time. Again, the choice of partitioning would introduce non-trivial variability into
the estimations of concordance. We could account for this variability by systemati-
cally estimating models and concordances for all possible partitions but were unable
to perform this due to computing constraints.
We rationalize our results due to our focus on model comparisons. The use of
the same observations to measure model performance means we overestimated the
performance. However, we aren’t interested in the actual model performance but the
differences between models. We compared models using the predicted risk scores of
each model on the same set of observations as would be done under a partitioning
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scheme. We assume that though each model’s performance is overestimated, the
relative difference is still a valid estimate of the true difference in predictive power.
Another important caveat with this work stems from the assumption that the
underlying RSEM count values are uncorrelated between observations and are free
of systematic error. Our data (and other available TCGA datasets) are the re-
sult of rolling collection by a number of participating centers. Recent work has
shown that inadvertent biases introduced per center or batch of samples are not ac-
counted for by RSEM and can introduce false positives in work that relies on RSEM
counts (Love et al., 2015).
3.4.4 FutureWork
Much of the work done is related to the preprocessing, cleaning, and filtering
of the data. A thorough investigation into the additional predictive power of isoform-
level covariates on cancer survival should include additional TCGA datasets following
the same procedure. A comparison of our results with a replication on non-TCGA
breast cancer survival data could also yield interesting findings.
Alternatively, testing the discriminative power of concordance using a known
data-generating process would aid in the interpretation of results on real world data.
This could also be used to validate our preprocessing and filtering techniques.
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